Human Nutrition Laboratory, The Swiss Federal Institute of Technology, Zürich, Switzerland.
Am J Clin Nutr. 2009 Nov;90(5):1280-7. doi: 10.3945/ajcn.2009.28129. Epub 2009 Sep 9.
Plasma hepcidin appears to be a major regulator of iron absorption and homeostasis, but there are few data in humans.
With the use of iron stable isotopes, we aimed to determine whether circulating hepcidin predicts dietary iron bioavailability, to quantify the amount of absorbed iron after oral iron loading, and to measure the plasma hepcidin response.
In the first study, young women (n = 98) with an iron status varying from iron deficiency anemia to iron sufficiency (women with serum ferritin concentrations 25-40 microg/L were not included) were given stable isotope-labeled test meals (n = 196) containing ferrous sulfate, ferrous fumarate, or ferric pyrophosphate, after which plasma hepcidin and iron bioavailability were measured. In the second study, iron-sufficient men (n = 4) were given 3.8- and 60-mg oral doses of labeled ferrous sulfate. The stable isotope appearance curve was determined, and the plasma hepcidin response was measured over 6 h.
In study 1, plasma hepcidin and plasma ferritin were strongly correlated (r = 0.79, P < 0.001). Plasma hepcidin significantly, but modestly, predicted iron bioavailability from ferrous sulfate and ferrous fumarate (r = -0.51 and -0.46, respectively; P < 0.0001) but not from ferric pyrophosphate (r = -0.30, P = 0.056, respectively). In study 2, the 3.8-mg dose increased mean circulating absorbed iron to a peak of 0.42 micromol/L at 60 min but did not increase plasma hepcidin, The 60-mg dose increased mean circulating absorbed iron to a peak of 5.9 micromol/L at 120 min and produced an approximately 30% increase in mean plasma hepcidin at 6 h (P < 0.01).
Plasma hepcidin is only a modest predictor of dietary iron bioavailability in humans. Oral iron loading, measured by stable-isotope appearance curves, increases circulating hepcidin.
血浆中的铁调素似乎是铁吸收和稳态的主要调节剂,但在人类中数据较少。
我们使用铁稳定同位素来确定循环铁调素是否可预测膳食铁的生物利用度,量化口服铁负荷后吸收的铁量,并测量血浆铁调素反应。
在第一项研究中,铁状态从缺铁性贫血到铁充足(血清铁蛋白浓度 25-40μg/L 的女性不包括在内)的年轻女性(n=98)接受了含有硫酸亚铁、富马酸亚铁或焦磷酸铁的稳定同位素标记测试餐(n=196),之后测量了血浆铁调素和铁的生物利用度。在第二项研究中,铁充足的男性(n=4)给予 3.8 和 60mg 口服剂量的标记硫酸亚铁。确定稳定同位素出现曲线,并在 6 小时内测量血浆铁调素反应。
在研究 1 中,血浆铁调素和血浆铁蛋白呈强相关(r=0.79,P<0.001)。血浆铁调素可显著但适度地预测硫酸亚铁和富马酸亚铁的铁生物利用度(r=-0.51 和-0.46,分别;P<0.0001),但不能预测焦磷酸铁的铁生物利用度(r=-0.30,P=0.056)。在研究 2 中,3.8mg 剂量使循环吸收铁的平均峰值增加到 60 分钟时的 0.42μmol/L,但未增加血浆铁调素。60mg 剂量使循环吸收铁的平均峰值增加到 120 分钟时的 5.9μmol/L,并使平均血浆铁调素增加约 30%,在 6 小时时达到(P<0.01)。
血浆铁调素只是人类膳食铁生物利用度的适度预测指标。通过稳定同位素出现曲线测量的口服铁负荷增加了循环铁调素。